Establishment Labs Q1 Revenue Jumps 38% to $67.2M, China Approval Boost
ESTA•Establishment Labs reported Q1 2026 revenue of $67.2 million, up 38% year-over-year, driven by 52% growth in Europe and 44% in Latin America. The company narrowed net loss to $3.2 million from $5.6 million a year ago and secured its first regulatory approval in China.
1. Q1 Financial Results
Establishment Labs delivered Q1 revenue of $67.2 million, representing a 38% increase from $48.7 million a year earlier. The company reduced its net loss to $3.2 million compared to $5.6 million in Q1 2025 and improved gross margin to 56% from 51%.
2. Regional Performance
Sales in Europe soared 52% year-over-year, reaching $25.8 million, while Latin American revenue grew 44% to $17.3 million. North America and other regions contributed $24.1 million, up 22%, driven by increased adoption of the Motiva implant portfolio.
3. Regulatory Update
Establishment Labs secured its first medical device approval in China for the Motiva Flora implant, paving the way for commercial launch in the world’s second-largest aesthetic market. Management expects China sales to begin in H2 2026 and contribute 10% of annual revenue by 2027.
